Analyst Consensus ?
ConsensusBuy39 ratings
Bullish3076.9%
Neutral923.1%
Bearish00.0%
Cigna Corporation · CI · FY2026 Q1 · Calendar Q2 2026
Cigna Beats Q1 Estimates, Raises Full-Year EPS Guidance on Specialty Strength and AI Investments
Cigna delivered a strong first quarter with $68.5 billion in revenue and adjusted EPS of $7.79, beating consensus on both lines. Management raised full-year adjusted EPS guidance to at least $30.35, driven by 20% year-over-year growth in Specialty and Care Services earnings and the launch of a rebate-free pharmacy benefits model called Signature. The company is simultaneously reshaping its portfolio -- exiting the individual exchange business, reviewing strategic alternatives for eviCore, and deploying AI capabilities that management says deliver approximately $2,000 in savings per member annually. A leadership transition to Brian Evanko as CEO effective July 1 adds execution risk alongside these strategic shifts, but management's tone was confident and near-term momentum appears solid. The stock's abnormal move of -1.6% on the report and subsequent drift of -4.5% suggest the market…
Reported Before market openNYSEHealthcare
$79.64B market cap
90quality score
Company context
Snapshot as of publicationCigna Group, established in 1792 and headquartered in Bloomfield, Connecticut, provides insurance products and related services across the United States. The company operates through two primary segments. Its Evernorth division offers a comprehensive array of coordinated and specialized health solutions, including pharmacy services, benefits administration, care management and delivery, and advanced intelligence solutions. These offerings cater to a diverse clientele, such as health plans, employers, government entities, and healthcare providers.…
Earnings scorecard
Reported versus consensus
Reported EPS
$7.79
Consensus $8
EPS surprise
+2.5%
Reported versus consensus
Reported revenue
$68.49B
Consensus $66.29B
Revenue surprise
+3.3%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$301.83Current
$225Low
$321.67Average
$415High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 29, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Bernstein | Outperform | Outperform | Maintain | Jul 9, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jun 8, 2026 |
| Barclays | Equal Weight | Overweight | Downgrade | May 26, 2026 |
| UBS | Buy | Buy | Maintain | May 22, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | May 20, 2026 |
| Deutsche Bank | Hold | Buy | Downgrade | May 20, 2026 |
| Guggenheim | Buy | Buy | Maintain | May 4, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | May 1, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | May 1, 2026 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | May 1, 2026 |
| Jefferies | Buy | Buy | Maintain | Apr 20, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Mar 3, 2026 |
| Truist Securities | Buy | Buy | Maintain | Feb 17, 2026 |
| TD Cowen | Buy | Buy | Maintain | Feb 9, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Nov 4, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Nov 4, 2025 |
| Baird | Outperform | Outperform | Maintain | Aug 14, 2025 |
| Raymond James | Strong Buy | Strong Buy | Maintain | May 5, 2025 |
| Stephens& Co. | Overweight | Overweight | Maintain | Jan 31, 2025 |
| Stephens & Co. | Overweight | Overweight | Maintain | Jan 31, 2025 |
| Oppenheimer | Outperform | Outperform | Maintain | Jan 31, 2025 |
| Edward Jones | Hold | Buy | Downgrade | Aug 18, 2023 |
| B of A Securities | Buy | Buy | Maintain | Aug 4, 2023 |
| SVB Leerink | Market Perform | Market Perform | Maintain | Feb 8, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Nov 7, 2022 |
| Loop Capital | Hold | Hold | Maintain | Jun 17, 2022 |
| Cowen & Co. | Outperform | Market Perform | Upgrade | May 9, 2022 |
| Seaport Global | Buy | Buy | Maintain | Nov 17, 2021 |
| BMO Capital | Outperform | Outperform | Maintain | Nov 8, 2021 |
| Citigroup | Buy | Buy | Maintain | Feb 5, 2021 |
| Wedbush | Neutral | Neutral | Maintain | Nov 25, 2020 |
| Susquehanna | Outperform | Neutral | Upgrade | Nov 25, 2020 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Nov 25, 2020 |
| Sterne Agee CRT | Buy | Neutral | Upgrade | Nov 25, 2020 |
| Sterne Agee | Neutral | Buy | Downgrade | Nov 25, 2020 |
| Monness Crespi Hardt | Buy | Buy | Maintain | Nov 25, 2020 |
| Leerink Swann | Outperform | Outperform | Maintain | Nov 25, 2020 |
| Bank of America | Buy | Buy | Maintain | Nov 25, 2020 |
| Monness, Crespi, Hardt | Neutral | Buy | Downgrade | Nov 5, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $301.83. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Bernstein | Analyst unavailable | $381 | $289.73 | +26.2% | Jul 8, 2026 |
| Wolfe Research | Justin Lake | $315 | $293.83 | +4.4% | Jun 16, 2026 |
| Mizuho Securities | Ann Hynes | $340 | $289.48 | +12.6% | Jun 8, 2026 |
| Barclays | Analyst unavailable | $304 | $286.24 | +0.7% | May 26, 2026 |
| UBS | Analyst unavailable | $400 | $282.02 | +32.5% | May 22, 2026 |
| Morgan Stanley | Analyst unavailable | $361 | $291.28 | +19.6% | May 20, 2026 |
| Deutsche Bank | Analyst unavailable | $302 | $291.28 | +0.1% | May 20, 2026 |
| Bernstein | Analyst unavailable | $371 | $279.35 | +22.9% | May 5, 2026 |
| Raymond James | Sarah James | $340 | $285.11 | +12.6% | May 1, 2026 |
| Robert W. Baird | Analyst unavailable | $337 | $285.6 | +11.7% | May 1, 2026 |
| Mizuho Securities | Analyst unavailable | $330 | $285.54 | +9.3% | May 1, 2026 |
| Barclays | Analyst unavailable | $310 | $290.58 | +2.7% | May 1, 2026 |
| Jefferies | Analyst unavailable | $330 | $278.64 | +9.3% | Apr 20, 2026 |
| Truist Financial | Analyst unavailable | $350 | $292.76 | +16.0% | Feb 17, 2026 |
| Deutsche Bank | Analyst unavailable | $304 | $291.17 | +0.7% | Feb 10, 2026 |
| Truist Financial | Analyst unavailable | $338 | $294.2 | +12.0% | Feb 9, 2026 |
| UBS | Analyst unavailable | $375 | $292.84 | +24.2% | Feb 9, 2026 |
| Barclays | Andrew Mok | $303 | $284.53 | +0.4% | Feb 6, 2026 |
| Mizuho Securities | Analyst unavailable | $325 | $283.91 | +7.7% | Jan 9, 2026 |
| Bernstein | Analyst unavailable | $307 | $287.1 | +1.7% | Jan 6, 2026 |
| Truist Financial | Analyst unavailable | $320 | $279.12 | +6.0% | Jan 5, 2026 |
| Barclays | Analyst unavailable | $305 | $279.12 | +1.1% | Jan 5, 2026 |
| Cowen & Co. | Charles Rhyee | $333 | $274.87 | +10.3% | Dec 15, 2025 |
| Guggenheim | Analyst unavailable | $318 | $273.57 | +5.4% | Dec 2, 2025 |
| Bernstein | Analyst unavailable | $294 | $271.57 | -2.6% | Nov 12, 2025 |
| UBS | Analyst unavailable | $294 | $268 | -2.6% | Nov 12, 2025 |
| Wells Fargo | Analyst unavailable | $300 | $264.66 | -0.6% | Nov 5, 2025 |
| Goldman Sachs | Scott Fidel | $330 | $258.62 | +9.3% | Nov 4, 2025 |
| Jefferies | David Windley | $310 | $244.41 | +2.7% | Nov 3, 2025 |
| Morgan Stanley | Erin Wright | $355 | $243 | +17.6% | Oct 31, 2025 |
| Barclays | Analyst unavailable | $300 | $245.1 | -0.6% | Oct 31, 2025 |
| Goldman Sachs | Scott Fidel | $370 | $295.41 | +22.6% | Oct 14, 2025 |
| Wells Fargo | Analyst unavailable | $354 | $302.99 | +17.3% | Oct 7, 2025 |
| Truist Financial | David MacDonald | $375 | $300.72 | +24.2% | Sep 2, 2025 |
| Robert W. Baird | Michael Ha | $372 | $286 | +23.2% | Aug 14, 2025 |
| Deutsche Bank | George Hill | $415 | $270.74 | +37.5% | Aug 5, 2025 |
| Guggenheim | Jason Cassorla | $388 | $333.82 | +28.5% | May 6, 2025 |
| Morgan Stanley | Erin Wright | $390 | $333.01 | +29.2% | May 5, 2025 |
| Barclays | Andrew Mok | $382 | $333.01 | +26.6% | May 5, 2025 |
| Wells Fargo | Stephen Baxter | $341 | $291.46 | +13.0% | Feb 4, 2025 |
| Piper Sandler | Jessica Tassan | $348 | $292.46 | +15.3% | Feb 3, 2025 |
| Raymond James | John Ransom | $360 | $294.21 | +19.3% | Jan 31, 2025 |
| Morgan Stanley | Erin Wright | $379 | $294.21 | +25.6% | Jan 31, 2025 |
| RBC Capital | Ben Hendrix | $355 | $294.21 | +17.6% | Jan 31, 2025 |
| Piper Sandler | Jessica Tassan | $400 | $338.8 | +32.5% | Jun 25, 2024 |
| Robert W. Baird | Michael Ha | $388 | $332.92 | +28.5% | May 29, 2024 |
| Jefferies | David Windley | $407 | $341.5 | +34.8% | May 6, 2024 |
| Oppenheimer | Michael Wiederhorn | $400 | $344.5 | +32.5% | May 3, 2024 |
| Raymond James | Sarah James | $400 | $344.5 | +32.5% | May 3, 2024 |
| RBC Capital | Ben Hendrix | $384 | $344.5 | +27.2% | May 3, 2024 |
| Raymond James | Sarah James | $372 | $324.06 | +23.2% | Feb 5, 2024 |
| Deutsche Bank | George Hill | $370 | $307.32 | +22.6% | Feb 1, 2024 |
| Leerink Partners | Analyst unavailable | $335 | $289 | +11.0% | Feb 8, 2023 |
| Raymond James | Analyst unavailable | $350 | $288.44 | +16.0% | Feb 7, 2023 |
| Stephens | Analyst unavailable | $370 | $289.12 | +22.6% | Feb 6, 2023 |
| Morgan Stanley | Analyst unavailable | $365 | $301.95 | +20.9% | Jan 6, 2023 |
| Morgan Stanley | Analyst unavailable | $347 | $320.9 | +15.0% | Nov 23, 2022 |
| Raymond James | John Ransom | $370 | $322.13 | +22.6% | Nov 6, 2022 |
| Truist Financial | David MacDonald | $330 | $272.63 | +9.3% | Jul 26, 2022 |
| Jefferies | David Windley | $271 | $273.75 | -10.2% | Jul 14, 2022 |
| Morgan Stanley | Ricky Goldwasser | $296 | $257.6 | -1.9% | Jun 22, 2022 |
| Deutsche Bank | George Hill | $284 | $244.52 | -5.9% | Jun 18, 2022 |
| Mizuho Securities | Ann Hynes | $291 | $263.98 | -3.6% | May 9, 2022 |
| Stephens | Analyst unavailable | $290 | $265.6 | -3.9% | Apr 20, 2022 |
| Truist Financial | David MacDonald | $290 | $254.12 | -3.9% | Apr 11, 2022 |
| Mizuho Securities | Ann Hynes | $266 | $240.51 | -11.9% | Mar 2, 2022 |
| Wells Fargo | Steve Baxter | $278 | $226.47 | -7.9% | Jan 6, 2022 |
| J.P. Morgan | Lisa Gill | $248 | $219.2 | -17.8% | Dec 21, 2021 |
| Goldman Sachs | Nathan Rich | $233 | $215.6 | -22.8% | Dec 14, 2021 |
| UBS | Kevin Caliendo | $244 | $216.63 | -19.2% | Nov 18, 2021 |
| Credit Suisse | A.J. Rice | $300 | $216.05 | -0.6% | Nov 8, 2021 |
| Evercore ISI | Michael Newshel | $230 | $211.09 | -23.8% | Nov 4, 2021 |
| Bank of America Securities | Kevin Fischbeck | $225 | $202.71 | -25.5% | Sep 10, 2021 |
| Cowen & Co. | Gary Taylor | $235 | $211.88 | -22.1% | Sep 9, 2021 |
| Raymond James | John Ransom | $275 | $208.14 | -8.9% | Aug 9, 2021 |
| Stephens | Scott Fidel | $270 | $206.32 | -10.5% | Aug 6, 2021 |
| Barclays | Steven Valiquette | $275 | $206.32 | -8.9% | Aug 6, 2021 |
| Oppenheimer | Michael Wiederhorn | $285 | $206.32 | -5.6% | Aug 6, 2021 |
| Cantor Fitzgerald | Steven Halper | $250 | $203.27 | -17.2% | Aug 5, 2021 |
| Wolfe Research | Justin Lake | $294 | $244.85 | -2.6% | Apr 26, 2021 |
Track every rating change on CI the moment it posts. Free to start.
Start freeMarket reaction
prior-close to event-session close
Stock move
-0.6%
Event window
SPY move
+1.0%
Same window
Abnormal move
-1.6%
Stock minus SPY
Volume
1.7×
Versus trailing sessions
Subsequent drift
-4.5%
Up to 20 sessions
CISPY benchmark
Follow CI with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Revenue of $68.5B vs. $66.3B estimated, a 3.3% surprise; EPS of $7.79 vs. $7.60 estimated, a 2.5% surprise. Full-year adjusted EPS guidance raised to at least $30.35. Specialty and Care Services earnings grew 20% year-over-year, driven by volume growth, biosimilar adoption, and the Shields Health Solutions investment. Strategic review of eviCore announced, alongside plans to exit the individual exchange business at year-end. Launch of the Signature rebate-free pharmacy model targeting 50% member adoption by 2028 with 30% lower drug prices. Agentic AI deployed for prescription processing; a predictive high-cost claimant model delivers approximately $2,000 in savings per member per year. Leadership transition: Brian Evanko becomes CEO on July 1, with David Cordani moving to Executive Chair.
Guidance delta
Management raised full-year adjusted EPS guidance to at least $30.35. The transcript analysis characterized guidance sentiment as 'raised.' No prior guidance figure was available in the supplied facts for direct comparison, but the direction is unambiguously upward. Capex outlook was not mentioned.
Key takeaways
- Q1 2026 revenue of $68.5B and adjusted EPS of $7.79 beat consensus by 3.3% and 2.5% respectively.
- Full-year adjusted EPS guidance raised to at least $30.35, reflecting confidence in specialty pharmacy and care services momentum.
- Specialty and Care Services earnings grew 20% YoY, supported by biosimilar adoption and the Shields investment.
- The rebate-free Signature pharmacy model targets 50% member adoption by 2028 with 30% lower drug prices.
- Portfolio reshaping includes exiting the individual exchange, evaluating eviCore alternatives, and concentrating on specialty and care services.
- AI and data analytics initiatives are generating approximately $2,000 per member in annual savings.
Management priorities
- Roll out the Signature rebate-free pharmacy model toward 50% member adoption by end-2028.
- Execute portfolio reshaping: exit the individual exchange business and evaluate strategic alternatives for eviCore.
- Invest in AI, data analytics, and predictive modeling for cost reduction and personalization.
- Expand Shields Health Solutions and CarepathRx specialty pharmacy capabilities.
- Hold an Investor Day in September to detail business advancements.
- Pursue targeted bolt-on M&A opportunities.
Related earnings events
HealthcareSources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-29T11:11:06.165542+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-29T11:11:06.162787+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.